

Palynziq - Non-PDL

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:	
HPP HPP Member Number:		Fax:	Phone:
Date of Birth:		Office Contact:	
Patient Primary Phone:		NPI:	PA PROMISe ID:
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP		Specialty Pharmacy (if applicable):	
Drug Name:		Strength:	
Quantity:		Refills:	
Directions:			
Diagnosis Code:		Diagnosis:	
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Has the patient been approved for treatment with Palynziq previously? If yes, go to Q2. If no, go to Q9.

Yes

No

Q2. Has the patient experienced any serious side effects (such as anaphylactic events) while being treated with Palynziq?

Yes

No

Q3. Has the patient been compliant with filling their prescription?

Yes

No

Q4. Is there documentation that the patient is stable on their current dose of Palynziq? Including documentation showing a blood phenylalanine concentration less than or equal to 600 micromol/L? Labs must be attached. If

Yes

No

Q5. Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 24 weeks of continuous treatment with 20 mg subcutaneously once daily?

Palynziq - Non-PDL

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. Is there a titration plan in place showing that the patient's dosage will be increased to 40 mg subcutaneously once daily for at least 16 weeks?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 16 weeks of continuous treatment with 40 mg subcutaneously once daily? Labs must be attached.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. Is there documentation showing the patient's dosage will be increased to a maximum of 60 mg subcutaneously once daily for at least 16 weeks?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. Is the patient 18 years of age or older?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. Is Palynziq being prescribed by or in consultation with a metabolic diseases specialist or a provider who specializes in the treatment of PKU?	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q11. Does the patient have a diagnosis of uncontrolled phenylketonuria confirmed by baseline blood phenylalanine concentrations greater than 600 micromol/L? Chart notes documenting diagnosis AND baseline labs must be attached.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q12. Has the patient tried non-pharmacological treatment options (such as restriction of dietary phenylalanine intake)? Notes must be attached showing the patient has tried and failed dietary restriction in consultation with a nutritionist.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	

Palynziq - Non-PDL

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q13. Does the patient have a documented trial and failure of or contraindication/intolerance to sapropterin dihydrochloride (sapropterin dihydrochloride will require Prior Authorization)? Documentation of contraindication/intolerance or trial and failure (at a dose of 20mg/kg for at least 1 month of therapy) must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Are both the patient and prescriber enrolled in The Palynziq REMS Program?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Has auto-injectable epinephrine been prescribed and has the patient been instructed on proper use and to have it on them at all times? Chart notes documenting that auto-injector epinephrine has been prescribed to the patient and counseling has been done must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Is there documentation that the initial dose will be administered under the supervision of a healthcare provider?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Is there documentation showing Palynziq will be initiated at the recommended induction dose?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q18. Is there documentation showing Palynziq will be titrated over at least 5 weeks after completing the 4-week induction period to an effective maintenance dosage?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q19. Is there documentation that Palynziq will not be used in combination with sapropterin dihydrochloride (if applicable)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Additional Information:</p>

Palynziq - Non-PDL

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

--

Prescriber Signature

Date

Updated for 2024